<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516606</url>
  </required_header>
  <id_info>
    <org_study_id>HD-K</org_study_id>
    <nct_id>NCT01516606</nct_id>
  </id_info>
  <brief_title>Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma</brief_title>
  <acronym>HD-K</acronym>
  <official_title>Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andres J. M. Ferreri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, phase II study on the activity and tolerability of high dose (2 g/day)
      oral clarithromycin for the treatment of relapsed or refractory extranodal marginal zone
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 6-month regimen of oral clarithromycin has been associated with a 35% ORR in patients with
      relapsed/refractory marginal zone B-cell lymphoma. Responses were more common among patients
      with conjunctival lymphoma. This could be explained at least in part by the elimination of
      clarithromycin by tears, suggesting that a higher tumor bioavailability of this antibiotic
      could result in a higher activity. Thus, a higher dose of clarithromycin could be associated
      with a higher tumor bioavailability in tissues other than the conjunctiva.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of responses</measure>
    <time_frame>The best clinical response at 6 months from trial registration</time_frame>
    <description>evaluation of activity in terms of global responses, complete responses and duration of responses</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>clarithromycin, oral, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin, oral, high dose</intervention_name>
    <description>2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total</description>
    <arm_group_label>clarithromycin, oral, high dose</arm_group_label>
    <other_name>klacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of extranodal extra-gastric marginal zone cell B
             lymphoma or gastric Helicobacter pylori positive lymphoma refractory to conventional
             antibiotic therapy, or H. pylori negative

          -  at least one measurable lesion

          -  relapsed or refractory lymphoma after systemic (chemotherapy, immunotherapy,
             antibiotic) or local (surgery or radiation) therapy

          -  ECOG PS &lt;/= 3

          -  no prior antibiotic therapy within 3 months before enrollment

        Exclusion Criteria:

          -  HIV 1-2 infection

          -  concomitant conventional or experimental antitumor therapy (chemotherapy,
             radiotherapy, immunotherapy, corticosteroids)

          -  severe inadequate liver (AST &lt;/=3 ULN, ALT &lt;/= 3 ULN, bilirubin &lt;/=3 ULN) or renal
             (creatinine &lt;/= 1.5 ULN) function

          -  allergy to macrolides

          -  concomitant malignant neoplasms within prior 5 years (with the exclusion of basal cell
             carcinoma, in situ spinocellular carcinoma of skin and cervix)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele Scientific Institute, Milano, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <phone>+30022643</phone>
    <phone_ext>7649</phone_ext>
    <email>ferreri.andres@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Govi, MD</last_name>
    <email>govi.silvia@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte Tabor</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <phone>+39022643</phone>
      <phone_ext>7649</phone_ext>
      <email>ferreri.andres@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Andres J. M. Ferreri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>MALT</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>extranodal</keyword>
  <keyword>relapsed or refractory extranodal marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

